The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS

På svenska

Author

Summary, in English

Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT symptoms (LUTS), have yielded favorable results. Thus, positive effects of the PDE 5 inhibitors sildenafil and tadalafil on symptoms and quality of life in men with LUTS, erectile dysfunction, and BPH have also been demonstrated. These effects may be due to effects on cGMP signaling and/or modification of afferent input from bladder, urethral, and prostate tissue. This review gives an update on the distribution of PDEs in structures relevant for LUT function, and discusses how inhibition of these enzymes can contribute to beneficial effects on LUTS. Information for the review was obtained from searches of the PubMed database, and from the authors' files.

Publishing year

2007

Language

English

Pages

928-933

Publication/Series

Neurourology and Urodynamics

Volume

26

Issue

6

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Urology and Nephrology

Keywords

  • prostatic hypertrophy(BPH)
  • (cGMP)
  • cyclic adenosine monophosphate (cAMP)
  • cyclic guanosine monophosphate
  • sildenafil
  • tadalafil
  • vinpocetine

Status

Published

ISBN/ISSN/Other

  • ISSN: 0733-2467